Successful treatment with dupilumab in a patient with severe, difficult to treat atopic dermatitis: Beware of symptomatic adrenal insufficiency due to abrupt discontinuation of potent topical corticosteroids
Files
Publication date
2018-06-08
Authors
Ariëns, Lieneke F.M.
Van Der Schaft, J.
Stades, A. M.E.
van de Woestijne, Anthonie A.
de Bruin-Weller, Marjolein
Editors
Advisors
Supervisors
Document Type
Editorial
Metadata
Show full item recordCollections
License
cc_by_nc
Abstract
Keywords
Administration, Cutaneous, Adrenal Cortex Hormones/administration & dosage, Adrenal Insufficiency/blood, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Betamethasone/administration & dosage, Biomarkers/blood, Dermatitis, Atopic/diagnosis, Drug Substitution/adverse effects, Humans, Hydrocortisone/administration & dosage, Male, Middle Aged, Remission Induction, Severity of Illness Index, Treatment Outcome, Dermatology, Case Reports, Journal Article
Citation
Ariens, L F M, van der Schaft, J, Stades, A M E, van de Woestijne, A A & De Bruin-Weller, M S 2018, 'Successful treatment with dupilumab in a patient with severe, difficult to treat atopic dermatitis : Beware of symptomatic adrenal insufficiency due to abrupt discontinuation of potent topical corticosteroids', Acta Dermato-Venereologica, vol. 98, no. 6, pp. 601-602. https://doi.org/10.2340/00015555-2936